An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations

Overview

Journal Anesthesiology

Specialty Anesthesiology

Date 2019 Jun 18

PMID 31206373

Citations 13

Authors

Carlos A Ibarra Moreno

Sally Hu

Natalia Kraeva

Frank Schuster

Stephan Johannsen

Henrik Rueffert

Werner Klingler

Luc Heytens

Sheila Riazi

Affiliations

Soon will be listed here.

Abstract

Background: Malignant hyperthermia (MH) is a potentially lethal disorder triggered by certain anesthetics. Mutations in the ryanodine receptor 1 (RYR1) gene account for about half of MH cases. Discordance between the low incidence of MH and a high prevalence of mutations has been attributed to incomplete penetrance, which has not been quantified yet. The authors aimed to examine penetrance of MH-diagnostic RYR1 mutations and the likelihood of mutation carriers to develop MH, and to identify factors affecting severity of MH clinical expression.

Methods: In this multicenter case-control study, data from 125 MH pedigrees between 1994 and 2017 were collected from four European registries and one Canadian registry. Probands (survivors of MH reaction) and their relatives with at least one exposure to anesthetic triggers, carrying one diagnostic RYR1 mutation, were included. Penetrance (percentage of probands among all genotype-positive) and the probability of a mutation carrier to develop MH were obtained. MH onset time and Clinical Grading Scale score were used to assess MH reaction severity.

Results: The overall penetrance of nine RYR1 diagnostic mutations was 40.6% (93 of 229), without statistical differences among mutations. Likelihood to develop MH on exposure to triggers was 0.25 among all RYR1 mutation carriers, and 0.76 in probands (95% CI of the difference 0.41 to 0.59). Penetrance in males was significantly higher than in females (50% [62 of 124] vs. 29.7% [30 of 101]; P = 0.002). Males had increased odds of developing MH (odds ratio, 2.37; 95% CI, 1.36 to 4.12) despite similar levels of exposure to trigger anesthetics. Proband's median age was 12 yr (interquartile range 6 to 32.5).

Conclusions: Nine MH-diagnostic RYR1 mutations have sex-dependent incomplete penetrance, whereas MH clinical expression is influenced by patient's age and the type of anesthetic. Our quantitative evaluation of MH penetrance reinforces the notion that a previous uneventful anesthetic does not preclude the possibility of developing MH.

Citing Articles

Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics.

Roberts D, Bastarache L, He J, Lewis A, Aka I, Shotwell M Pharmacogenet Genomics. 2025; 35(2):65-72.

PMID: 39745345 PMC: 11695055. DOI: 10.1097/FPC.0000000000000551.

Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselection.

Kingsmore S, Wright M, Smith L, Liang Y, Mowrey W, Protopsaltis L Am J Hum Genet. 2024; 111(12):2618-2642.

PMID: 39642867 PMC: 11639087. DOI: 10.1016/j.ajhg.2024.10.021.

Current Practices in Pharmacogenomics.

Ramsey L, Prows C, Tang Girdwood S, Van Driest S Pediatr Clin North Am. 2023; 70(5):995-1011.

PMID: 37704356 PMC: 10865383. DOI: 10.1016/j.pcl.2023.05.010.

Rebounds of sevoflurane concentration during simulated trigger-free pediatric and adult anesthesia.

Zumsande S, Thoben C, Dennhardt N, Krauss T, Sumpelmann R, Zimmermann S BMC Anesthesiol. 2023; 23(1):196.

PMID: 37291484 PMC: 10249316. DOI: 10.1186/s12871-023-02148-3.

Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group.

Tan L, Teng Y, Yu H, Liu C, Xiao K, Yin J J Multidiscip Healthc. 2023; 15:3005-3013.

PMID: 36601426 PMC: 9807132. DOI: 10.2147/JMDH.S387208.

References

Grievink H, Stowell K . Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia. Orphanet J Rare Dis. 2010; 5:10. PMC: 2895584. DOI: 10.1186/1750-1172-5-10. View

Britt B, KALOW W . Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970; 17(4):293-315. DOI: 10.1007/BF03004694. View

Denborough M, Galloway G, Hopkinson K . Malignant hyperpyrexia and sudden infant death. Lancet. 1982; 2(8307):1068-9. DOI: 10.1016/s0140-6736(82)90005-8. View

Lopez J, Kaura V, Diggle C, Hopkins P, Allen P . Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1. Br J Anaesth. 2018; 121(4):953-961. PMC: 6208291. DOI: 10.1016/j.bja.2018.07.008. View

Riazi S, Kraeva N, Muldoon S, Dowling J, Ho C, Petre M . Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference. Can J Anaesth. 2014; 61(11):1040-9. PMC: 4276369. DOI: 10.1007/s12630-014-0227-5. View

Migita T, Mukaida K, Kobayashi M, Hamada H, Kawamoto M . The severity of sevoflurane-induced malignant hyperthermia. Acta Anaesthesiol Scand. 2011; 56(3):351-6. DOI: 10.1111/j.1399-6576.2011.02573.x. View

Robinson R, Carpenter D, Shaw M, Halsall J, Hopkins P . Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 2006; 27(10):977-89. DOI: 10.1002/humu.20356. View

Hirshey Dirksen S, Larach M, Rosenberg H, Brandom B, Parness J, Lang R . Special article: Future directions in malignant hyperthermia research and patient care. Anesth Analg. 2011; 113(5):1108-19. PMC: 3184381. DOI: 10.1213/ANE.0b013e318222af2e. View

Toppin P, Chandy T, Ghanekar A, Kraeva N, Beattie W, Riazi S . A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene. Can J Anaesth. 2010; 57(7):689-93. DOI: 10.1007/s12630-010-9314-4. View

10.

Wolak S, Rucker B, Kohlschmidt N, Doetsch S, Bartsch O, Zechner U . [Homozygous and compound heterozygous RYR1 mutations. New findings on prevalence and penetrance of malignant hyperthermia]. Anaesthesist. 2014; 63(8-9):643-50. DOI: 10.1007/s00101-014-2351-6. View

11.

Kemp D, Choong L . Malignant hyperthermia and the conscious patient. Aust N Z J Surg. 1988; 58(5):423-7. DOI: 10.1111/j.1445-2197.1988.tb01092.x. View

12.

Klingler W, Heiderich S, Girard T, Gravino E, Heffron J, Johannsen S . Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study. Orphanet J Rare Dis. 2014; 9:8. PMC: 3896768. DOI: 10.1186/1750-1172-9-8. View

13.

Monnier N, Krivosic-Horber R, Payen J, Kozak-Ribbens G, Nivoche Y, Adnet P . Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002; 97(5):1067-74. DOI: 10.1097/00000542-200211000-00007. View

14.

Riazi S, Kraeva N, Hopkins P . Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. Anesthesiology. 2017; 128(1):168-180. PMC: 5726912. DOI: 10.1097/ALN.0000000000001878. View

15.

Kraeva N, Heytens L, Jungbluth H, Treves S, Voermans N, Kamsteeg E . Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy. Neuromuscul Disord. 2015; 25(7):567-76. DOI: 10.1016/j.nmd.2015.04.007. View

16.

Yang T, Riehl J, Esteve E, Matthaei K, Goth S, Allen P . Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology. 2006; 105(6):1164-75. DOI: 10.1097/00000542-200612000-00016. View

17.

Yuen B, Boncompagni S, Feng W, Yang T, Lopez J, Matthaei K . Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage. FASEB J. 2011; 26(3):1311-22. PMC: 3289506. DOI: 10.1096/fj.11-197582. View

18.

Cooper D, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H . Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet. 2013; 132(10):1077-130. PMC: 3778950. DOI: 10.1007/s00439-013-1331-2. View

19.

Ording H . Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985; 64(7):700-4. View

20.

Lu Z, Rosenberg H, Li G . Prevalence of malignant hyperthermia diagnosis in hospital discharge records in California, Florida, New York, and Wisconsin. J Clin Anesth. 2017; 39:10-14. DOI: 10.1016/j.jclinane.2017.03.016. View